Clinical efficacy High impact sales opportunity with NOxyCure showing strong clinical results including 88.6% wound area reduction versus 46.9% with standard care, eight weeks faster outcomes, and potential per-patient cost savings of $10k–$14k. Target medical centers treating chronic wounds and payers looking to reduce costs will be primary buyers.

Strategic partnerships Active pursuit of corporate manufacturing and distribution partners presents a doorway for BD collaboration with contract manufacturers, large medtech distributors, and integrated health systems to scale production, leverage existing channels, and accelerate market reach.

Early-stage funding Series round open for investors signals readiness for capital to scale. DAC and biotech-focused funds, strategic corporate venture arms, and clinical development collaborators could be engaged to secure growth capital and strategic value.

Market expansion Target the $3B+ advanced wound care market by positioning NOxyCure as a first-in-class NO delivery platform capable of antimicrobial action, anti-biofilm effects, and enhanced healing, appealing to hospitals, wound care clinics, and long-term care facilities.

Technology readiness Dual-stage NO delivery with precise wound-bed dosing, and a scalable tech stack aligned with cloud-based operations suggest opportunities to partner with health IT vendors and large CROs for streamlined data capture, remote monitoring, and value-based care demonstrations.